This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.
This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments. All patients who received at least one dose of Fostamatinib between October 1st, 2021 and April 1st, 2023 outside interventional clinical trials in Italy in the participating centers will be invited to participate in the study. Every patient will be observed for at least 6 months until October 1st, 2023.
Study Type
OBSERVATIONAL
Enrollment
95
Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
AON SS. ANTONIO E BIAGIO E C. ARRIGO - SS emostasi e trombosi
Alessandria, Italy
Number of ITP patients who receive Fostamatinib
effectiveness evaluation of fostamatinib
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
SOD Clinica Ematologica AOU Ospedali Riuniti Umberto I GM Lancisi G Salesi
Ancona, Italy
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro
Bari, Italy
Istituto di Ematologia "Lorenzo e A. Seragnoli" Policlinico S. Orsola
Bologna, Italy
Asst Degli Spedali Civili Di Brescia - Uo Ematologia
Brescia, Italy
Unità di Onco-Ematologia - Azienda Ospedaliera Garibaldi
Catania, Italy
Ematologia A.O.U. Careggi
Florence, Italy
Milano Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia
Milan, Italy
Ematologia AOU Università degli Studi di Napoli "Federico II"
Naples, Italy
.C.D.U. Ematologia - Università del Piemonte Orientale Amedeo Avogadro
Novara, Italy
...and 11 more locations